Literature DB >> 8070015

Ifosfamide enantiomers: pharmacokinetics in children.

V K Prasad1, S A Corlett, K Abaasi, D Heney, I Lewis, H Chrystyn.   

Abstract

Ifosfamide, like other oxazaphosphorine drugs, is chiral and there is some evidence, mainly from animal studies, of stereo-selective differences in metabolism, excretion and cytotoxic activity between the two enantiomers. The pharmacokinetics of racemic ifosfamide (RAC-IFO), R-ifosfamide (R-IFO) and S-ifosfamide (S-IFO) were studied in five children who received intravenous therapy with racemic ifosfamide on 3 consecutive days. The clearance of S-IFO was greater than that of R-IFO. The clearance value at the end of the infusion was faster than the respective rate measured at the beginning of or during the ifosfamide regimens in four children and, therefore, suggests autoinduction of elimination of both enantiomers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070015     DOI: 10.1007/bf00685573

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

1.  Pharmacokinetics of divided-dose ifosfamide.

Authors:  R L Nelson; L M Allen; P J Creaven
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

2.  Enantiomers of cyclophosphamide and iphosphamide.

Authors:  P B Farmer
Journal:  Biochem Pharmacol       Date:  1988-01-01       Impact factor: 5.858

3.  Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates.

Authors:  H Kuśnierczyk; C Radzikowski; M Paprocka; W Budzyński; J Rak; R Kinas; K Misiura; W Stec
Journal:  J Immunopharmacol       Date:  1986

4.  Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism.

Authors:  L D Lewis; D L Fitzgerald; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

5.  Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice.

Authors:  D Masurel; P J Houghton; C L Young; I W Wainer
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

6.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  [Separation and pharmaco-toxicological studies of the enantiomers of Ifosfamide].

Authors:  G Blaschke; P Hilgard; J Maibaum; U Niemeyer; J Pohl
Journal:  Arzneimittelforschung       Date:  1986-10

8.  Enantiomeric separation of R- and S-ifosfamide and their determination in serum from clinical subjects.

Authors:  S A Corlett; H Chrystyn
Journal:  J Chromatogr B Biomed Appl       Date:  1994-03-18
  8 in total
  4 in total

1.  Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

Authors:  T Kerbusch; A D Huitema; J Ouwerkerk; H J Keizer; R A Mathôt; J H Schellens; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

3.  Stereoselective pharmacokinetics of ifosfamide in male and female rats.

Authors:  J J Wang; H Lu; K K Chan
Journal:  AAPS PharmSci       Date:  2000

4.  Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.

Authors:  S A Corlett; D Parker; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.